natgillin/translations-raw huggingface dataset:
You may be monitored for side effects associated with excessive platelets such as blood clots (see section 2, ‘Warnings and precautions', and section 4, ‘Possible side effects'). 
Mogoče vas bodo opazovali glede neželenih učinkov, povezanih s čezmernim številom krvnih ploščic, na primer krvnih strdkov (glejte poglavje 2, ‘Opozorila in previdnostni ukrepi', in poglavje 4, ‘Možni neželeni učinki').
What Mulpleo is and what it is used for 
Kaj je zdravilo Mulpleo in za kaj ga uporabljamo
LUSU = lusutrombopag; Q1 = 25th percentile; Q3 = 75th percentile [a] P-value was calculated by the van Elteren test with platelet transfusion status as stratum. 
LUSU = lusutrombopag; Q1 = 25. percentil; Q3 = 75. percentil [a] Vrednost p je bila izračunana z van Elternovim testom s statusom transfuzije trombocitov kot stratumom.
Signs of a blood clot: look out for any of the signs below: 
Znaki krvnega strdka: bodite pozorni na tele znake:
Thus, the data from the toxicology program in these animals do not present potential adverse effects related to exaggerated pharmacology in humans. 
Zato podatki iz toksikološkega programa pri teh živalih niso pokazali možnih neželenih učinkov, povezanih s pretiranim farmakološkim odzivom pri ljudeh.
Mulpleo is used to reduce the risk of bleeding during surgery and other procedures (including tooth extractions and endoscopy). 
Zdravilo Mulpleo se uporablja za zmanjšanje nevarnosti krvavitve med operacijo in drugimi posegi (vključno z izdrtjem zob in endoskopijo).
The recommended dose is 3 mg lusutrombopag once daily for 7 days. 
Odmerjanje Priporočeni odmerek je 3 mg lusutrombopaga enkrat na dan 7 dni.
If you have taken more Mulpleo than you should, talk to your doctor or go to the hospital. 
Če ste vzeli več zdravila Mulpleo, kot bi ga smeli, se pogovorite z zdravnikom ali pojdite v bolnišnico.
Environmental risk assessment studies have shown that lusutrombopag has the potential to be very persistent, very bioaccumulative and toxic to the environment. 
Ocena tveganja za okolje (Environmental Risk Assessment - ERA) Študije tveganja za okolje so pokazale, da je lusutrombopag zelo trdovraten, zelo bioakumulativen in toksičen za okolje.
Pharmacotherapeutic group: Antihemorrhagics, other systemic hemostatics, ATC code: B02BX07 
Farmakoterapevtska skupina: Antihemoragiki, drugi hemostatiki za sistemsko zdravljenje, oznaka ATC: B02BX07.
These patients should be clinically monitored when treated with lusutrombopag. 
Te bolnike je treba klinično spremljati, kadar jih zdravimo z lusutrombopagom.
[b] Cochran-Mantel-Haenszel test with baseline platelet count as stratum. 
[b] Cochran-Mantel-Haenszlov test z izhodiščnim številom trombocitov kot stratumom.
Geometric mean (%CV) other than for Tmax, which is median (range). 
Geometrična sredina (% CV (odstotni koeficient variacije)), razen za Tmax, ki je mediana (razpon).
Since the protein-binding rate in serum of lusutrombopag is high, haemodialysis is not thought to be effective. 
Ker je stopnja vezave lusutrombopaga na beljakovine v serumu velika, menimo, da hemodializa ni učinkovita.
It is given to adults who have low numbers of platelets because of chronic liver disease. 
Dajejo ga odraslim, ki imajo majhno število krvnih ploščic zaradi kronične bolezni jeter.
Platelet counts should be measured frequently and the condition of patients should be observed closely. 
Pogosto je treba meriti število trombocitov in skrbno opazovati bolnikovo stanje.
Lusutrombopag is rarely excreted into urine (approximately 1%). 
Lusutrombopag se zelo malo izloča z urinom (približno 1 %).
Do not breast-feed during treatment with Mulpleo, as it is not known if the medicine passes into milk. 
Ne dojite med zdravljenjem z zdravilom Mulpleo, ker ni znano, ali zdravilo prehaja v mleko.
Eight lusutrombopag-treated subjects and 2 placebo-treated subjects received less than 7 days of treatment as they met the criterion for a responder prior to Day 7. 
Osem bolnikov, zdravljenih z lusutrombopagom, in 2 bolnika, ki sta prejemala placebo, so prejeli manj kot 7 dni zdravljenja, ker so pred 7. dnem izpolnili merilo za odziv na zdravljenje.
If you have severe liver disease, tell your doctor before taking Mulpleo. 
Če imate hudo bolezen jeter, povejte zdravniku, preden vzamete zdravilo Mulpleo.
What Mulpleo is and what it is used for What you need to know before you take Mulpleo How to take Mulpleo 
Kaj je zdravilo Mulpleo in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Mulpleo Kako jemati zdravilo Mulpleo
Meanwhile, the short thoracolumbar supernumerary ribs were observed at doses without maternal toxicity. 
medtem ko so kratka torakolumbalna nadštevilna rebra ugotavljali pri odmerkih brez toksičnosti za mater.
If a dose is missed it should be taken as soon as possible. 
Če bolnik kak odmerek izpusti, ga mora vzeti čimprej.
No dosage adjustment is expected for these patients. 
Pri teh bolnikih ne pričakujemo, da bo treba odmerek prilagoditi.
Do not change the dose or schedule for taking Mulpleo unless your doctor or pharmacist tells you to. 
Ne spreminjajte odmerka ali časovnega razporeda jemanja zdravila Mulpleo, če vam zdravnik ali farmacevt ne naroči drugače.
Study drug was administered orally for up to 7 days. 
Raziskovano zdravilo so dajali peroralno do 7 dni.
Drug interactions via inhibition and induction of any CYP4A enzymes have not been reported in clinical use. 
O interakcijah med zdravili preko inhibicije in indukcije katerih koli encimov CYP4A v klinični uporabi niso poročali.
If you stop taking Mulpleo 
Če ste prenehali jemati zdravilo Mulpleo
PHARMACEUTICAL FORM AND CONTENTS 7 film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 7 filmsko obloženih tablet
Caution should be exercised with respect to thromboembolic events after invasive procedures as well as post-treatment regardless of platelet counts. 
Potrebna je previdnost glede trombemboličnih dogodkov in to tako po invazivnih posegih kot tudi po zdravljenju ne glede na število trombocitov.
In rats, lusutrombopag and its metabolites are excreted in milk, and the concentrations in milk decreased as with those in plasma. 
Pri podganah se lusutrombopag in njegovi presnovki izločajo v mleko, koncentracije v mleku pa so se zmanjšale tako kot koncentracije v plazmi.
The key secondary endpoints in Studies M0631 and M0634 were 
Ključni sekundarni končni stanji v študijah M0631 in M0634 sta bili
Interferon preparations have been known to reduce platelet counts, therefore, this should be considered when co-administering lusutrombopag with interferon preparations. 
Znano je, da pripravki interferona zmanjšajo število trombocitov, zato je treba to upoštevati, kadar dajemo lusutrombopag skupaj s pripravki interferona.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'. 
Zdravilo Mulpleo vsebuje malo natrija To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na tableto, kar v bistvu pomeni ‘brez natrija'.
Platelet Count (*10^4/uL) 
Število trombocitov (*10^4/ul)
Lusutrombopag is absorbed with a peak concentration occurring 6 to 8 hours after oral administration. 
Absorpcija Lusutrombopag se absorbira z najvišjo koncentracijo, ki nastopi 6 do 8 ur po peroralnem dajanju.
The pharmacokinetics of lusutrombopag was similar in both healthy subjects and the chronic liver disease population. 
Farmakokinetika lusutrombopaga je bila podobna tako pri zdravih osebah kot v populaciji s kronično boleznijo jeter.
The efficacy and safety of lusutrombopag have not been established when administered before laparotomy, thoracotomy, open-heart surgery, craniotomy or excision of organs. 
Učinkovitost in varnost lusutrombopaga nista bili ugotovljeni za dajanje pred laparotomijo, torakotomijo, operacijo na odprtem srcu, kraniotomijo ali odstranitvijo organov.
INFORMATION IN BRAILLE Mulpleo 
PODATKI V BRAILLOVI PISAVI Mulpleo
In the placebo group, 94/107 subjects (87.9%) received the study drug for 7 days. 
V skupini s placebom je 94/107 bolnikov (87,9 %) prejemalo raziskovano zdravilo 7 dni.
Lusutrombopag was not genotoxic when tested in a bacterial reverse mutation test, a chromosomal aberration test with cultured Chinese hamster lung cells, or an in vivo micronucleus test with mouse bone marrow cells. 
Lusutrombopag ni bil genotoksičen, ko so ga testirali s testom povratnih mutacij pri bakterijah, testom kromosomskih aberacij na kulturi pljučnih celic kitajskega hrčka ali mikronukleusnim testom in vivo s celicami mišjega kostnega mozga.
Lusutrombopag is not considered to affect the pharmacokinetics of co-administered medicinal products that are substrates of these enzymes or transporters. 
Menimo, da lusutrombopag ne vpliva na farmakokinetiko sočasno dajanih zdravil, ki so substrati teh encimov ali prenašalcev.
Lusutrombopag should be used when risk for bleeding is considered to be high according to clinical laboratory test values such as platelet counts and of the coagulation-fibrinolysis system, clinical symptoms and type of invasive procedure. 
Lusutrombopag je treba uporabiti, kadar menimo, da je tveganje krvavitve veliko, sodeč po vrednostih kliničnih laboratorijskih preiskav, na primer števila trombocitov, in sistema koagulacija-fibrinoliza, kliničnih simptomih in vrsti invazivnega posega.
Overdose may induce an excessive increase of platelet counts, and it may subsequently provoke a medically susceptible state to cause thrombosis and thromboembolism. 
Preveliko odmerjanje lahko povzroči čezmerno zvečanje števila trombocitov in lahko pozneje izzove zdravstveno stanje, za katerega je verjetno, da bo povzročilo trombozo in trombembolizem.
Mulpleo should be used with contraception (see sub-section Pregnancy and section 5.3). 
Zdravilo Mulpleo je treba uporabljati skupaj s kontracepcijo (glejte podpoglavje Nosečnost in poglavje 5.3).
What you need to know before you take Mulpleo 
Kaj morate vedeti, preden boste vzeli zdravilo Mulpleo
In order to allow an overall comparison of the results across Studies M0631 and M0634, as presented in Table 2 to Table 5, data from study M0631 was reanalysed according to the primary endpoint for study M0634. 
Da bi omogočili celotno primerjavo rezultatov študij M0631 in M0634, ki je predstavljena v preglednicah 2 do 5, so ponovno analizirali podatke iz študije M0631 v skladu s primarnim opazovanim dogodkom študije M0634.
The accumulation ratios of the Cmax and the AUC are approximately 2 at once-daily multiple doses and the steady-state of the plasma concentration of lusutrombopag appear to be achieved after Day 5. 
Razmerji kopičenja Cmax in AUC sta približno 2 pri večkratnih odmerkih enkrat na dan in zdi se, da se stanje dinamičnega ravnovesja plazemske koncentracije lusutrombopaga doseže po 5. dnevu.
Use in patients with chronic liver disease undergoing invasive procedures 
Uporaba pri bolnikih s kronično boleznijo jeter, pri katerih so potrebni invazivni posegi
Therefore, inducers and inhibitors of CYP4A enzymes including CYP4A11 are unlikely to affect the pharmacokinetics of lusutrombopag. 
Zato ni verjetno, da bi induktorji in inhibitorji encimov CYP4A, vključno s CYP4A11, vplivali na farmakokinetiko lusutrombopaga.
Lusutrombopag has no known influence on the ability to drive and use machines. 
Lusutrombopag nima znanega vpliva na sposobnost vožnje in upravljanja strojev.
Studies in animals have shown lusutrombopag is secreted in the milk of lactating rats (see section 5.3). 
Študije na živalih so pokazale, da se lusutrombopag izloča v mleko doječih podgan (glejte poglavje 5.3).
Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis. 
Lusutrombopag deluje na hematopoetične matične celice in na transmembransko domeno človeških TPO receptorjev, izraženih v megakariocitih, tako da spodbuja megakariocite k proliferaciji in diferenciaciji preko podobne poti za prenos signalov za zvečanje izdelave, kot jo uporablja endogeni TPO, kar povzroči trombocitopoezo.
In addition to subjects who received platelet transfusion, subjects who did not receive an invasive procedure regardless of the reason were considered as receiving platelet transfusion. 
Poleg bolnikov, ki so prejeli transfuzijo trombocitov, so tudi bolnike, ki ne glede na razlog niso imeli invazivnega posega, šteli, da so prejeli transfuzijo trombocitov.
In addition, although no dose adjustment is required in these subjects, platelet count should be measured at least once approximately 5 days after the first dose and as necessary thereafter. 
Čeprav pri teh bolnikih prilagajanje odmerka ni potrebno, je treba število trombocitov določiti vsaj enkrat približno 5 dni po prvem odmerku, pozneje pa po potrebi.
This limited data suggested no abnormal pattern of platelet count rise in this subpopulation. 
Ti omejeni podatki niso pokazali nenormalnega vzorca zvečanja števila trombocitov v tej podskupini.
It is unknown whether lusutrombopag or its metabolites are excreted in human milk. 
Ni znano, ali se lusutrombopag ali njegovi presnovki izločajo v materino mleko pri ljudeh.
Pregnancy and breast-feeding Do not take Mulpleo if you are pregnant unless your doctor specifically recommends it. 
Ne vzemite zdravila Mulpleo, če ste noseči, razen če vam ga zdravnik posebej priporoči.
In Study M0631, 96 subjects received lusutrombopag or placebo once daily: 48 subjects in the lusutrombopag group and 48 subjects in the placebo group. 
V študiji M0631 je 96 bolnikov prejemalo lusutrombopag ali placebo enkrat na dan: 48 bolnikov v skupini z lusutrombopagom in 48 bolnikov v skupini s placebom.
In vitro studies revealed that CYP4 enzymes including CYP4A11 and partially CYP3A4 enzyme contributed to ω-oxidation to form 6-hydroxylated lusutrombopag. 
Študije in vitro so pokazale, da so encimi CYP4, vključno z encimom CYP4A11 in deloma CYP3A4 prispevali k ω-oksidaciji, tako da je nastal 6-hidroksilirani lusutrombopag.
Mulpleo is supplied in aluminium blisters in a carton containing 7 film-coated tablets. 
Zdravilo Mulpleo je na voljo v aluminijastih pretisnih omotih v kartonski škatli, ki vsebuje 7 filmsko obloženih tablet.
Certain people may have a higher risk of blood clots, including people with liver disease, and medicines like Mulpleo could make this problem worse. 
Zvečano tveganje za nastanek krvnih strdkov Pri nekaterih ljudeh (sem spadajo ljudje z boleznijo jeter) je tveganje za nastanek krvnih strdkov mogoče večje in zdravila, kot je Mulpleo, lahko ta problem poslabšajo.
In the lusutrombopag group, 73/107 subjects (68.2%) received the study drug for 7 days. 
V skupini z lusutrombopagom je 73/107 bolnikov (68,2 %) prejemalo raziskovano zdravilo 7 dni .
In Study M0634, 215 subjects were randomised in the study: 108 in the lusutrombopag 3 mg group and 107 in the placebo group. 
V študiji M0634 so randomizirali 215 bolnikov: 108 v skupini z lusutrombopagom 3 mg in 107 v skupini s placebom.
Each box contains 7 film-coated tablets. 
Ena škatla vsebuje 7 filmsko obloženih tablet.
Lusutrombopag should only be used in such patients if the expected benefit outweighs the expected risks (see sections 4.2 and 5.2). 
Lusutrombopag se sme pri takih bolnikih uporabljati samo, če pričakovana korist odtehta pričakovana tveganja (glejte poglavji 4.4 in 5.2).
The mean (% coefficient of variation) apparent volume of distribution during the terminal phase of lusutrombopag in healthy adult subjects (n = 16) was 39.5 L (23.5%). 
navidezni volumen porazdelitve med terminalno fazo lusutrombopaga pri zdravih odraslih preiskovancih (n = 16) je bil 39,5 l (23,5 %).
Lusutrombopag has low potential to inhibit CYP enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5), and to induce both CYP enzymes (CYP1A2, 2C9, and 3A4) and UGT enzymes (UGT1A2, 1A6, and 2B7). 
Lusutrombopag ima majhen potencial za inhibiranje encimov CYP (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 in 3A4/5) in za induciranje tako encimov CYP (CYP1A2, 2C9 in 3A4) kot UGT (UGT1A2, 1A6 in 2B7).
Pre- and post-natal development 
Pred- in poporodni razvoj
In patients with thrombosis or thromboembolism, with a history of thrombosis or thromboembolism, with absence of hepatopetal blood flow in the main trunk of the portal vein, or patients with congenital coagulopathy the risk for thrombosis or thromboembolism may increase. 
Pri bolnikih s trombozo ali trombembolizmom, z anamnezo tromboze ali trombembolizma, pri tistih brez hepatopetalnega toka krvi v glavnem deblu portalne vene ali bolnikih s prirojeno koagulopatijo se lahko tveganje tromboze ali trombembolizma zveča.
Lusutrombopag was excreted mainly via faecal route in humans (approximately 83% into faeces and 1% into urine). 
Lusutrombopag se je pri ljudeh izločal predvsem z blatom (približno 83 % v blatu in 1 % v urinu).
Adverse reaction - Common 
Neželeni učinek - pogosti
• Blood clot in the liver (portal vein thrombosis) 
• krvni strdek v jetrih (tromboza portalne vene),
OPA/Aluminium foil/PVC film blister with push through aluminium lidding foil, packed in a cardboard box. 
Pretisni omot iz OPA/aluminijaste folije/PVC prevleke, pakiran v kartonski škatli.
Portal vein thrombosis Skin and subcutaneous tissue disorders Rash a Category of frequency: very common (≥1/10), common (≥1/100 to <1/10) , uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) , and very rare (<1/10,000) 
Bolezni kože in podkožja izpuščaj a Kategorije pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
Neither food (including high-fat and high-calorie diet) nor co-administration with calcium has a clinically meaningful effect on the pharmacokinetics of lusutrombopag. 
Niti hrana (vključno z dieto z veliko maščob in veliko kalorij) niti sočasno dajanje s kalcijem nimata klinično pomembnega vpliva na farmakokinetiko lusutrombopaga.
The changes were also noted in F1 pups on postnatal day (PND) 4 at 12.5 mg/kg/day or more in the preand postnatal development study; however, F1 mature animals showed no full and short thoracolumbar supernumerary rib. 
Spremembe so v študiji pred- in poporodnega razvoja opazili tudi pri F1 mladičih na poporodni dan (postnatal day - PND) 4 pri 12,5 mg/kg/dan ali več; vendar F1 zrele živali niso imele popolnega ali kratkega torakolumbalnega nadštevilnega rebra.
Lusutrombopag is not recommended during pregnancy and in women of child-bearing potential not using contraception. 
Lusutrombopaga ne uporabljajte pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Do not chew, break, or crush the tablet. 
Tablete ne žvečite, razdelite ali zdrobite.
Mulpleo should not be administered to breast-feeding women as it was excreted in mammary milk in animals. 
Zdravilo Mulpleo se ne sme dajati doječim materam, ker se je pri živalih izločalo v materino mleko.
Due to limited information available, the safety and efficacy of Mulpleo in patients with severe hepatic impairment (Child-Pugh class C) have not been established (see sections 4.4 and 5.1). 
Ker je na voljo malo podatkov, varnost in učinkovitost zdravila Mulpleo pri bolnikih s hudo okvaro jeter (razred C po Child-Pughu) nista bili dokazani (glejte poglavji 4.4 in 5.1).
High dose (10 mg/kg/day) and long-term treatment (8 weeks) of lusutrombopag has a potential risk of fibrosis in the bone marrow via human TPO receptor based on the results of study in TPOR-Ki/Shi mice with chimeric human transmembrane domain TPO receptor knocked-in to the mouse TPO receptor. 
Veliki odmerki (10 mg/kg/dan) in dolgoročno zdravljenje (8 tednov) z lusutrombopagom prinašajo možno tveganje fibroze v kostnem mozgu preko človeškega receptorja za TPO na podlagi rezultatov študije na miših TPOR-Ki/Shi s himerno človeško transmembransko domeno receptorja za TPO,
Geometric mean of t1/2 (% coefficient of variation), was 38.3 hours (18.7%) after multiple oral dose of 3 mg lusutrombopag. 
Geometrična sredina t1/2 (odstotni koeficient variacije) po večkratnih peroralnih 3-miligramskih odmerkih lusutrombopaga je bila 38,3 ure (18,7 %).
Warnings and precautions Talk to your doctor: - if you are at risk of blood clots in your veins or arteries, or if you previously have had blood clots - if you have severe liver disease - if your spleen has been removed - if you are having interferon treatment. 
Opozorila in previdnostni ukrepi Posvetujte se z zdravnikom: - če pri vas obstaja tveganje za nastanek krvnih strdkov v vaših venah ali arterijah, ali če ste kdaj prej že imeli krvne strdke;
Table 5 Duration of the increase in platelet count to ≥ 50,000/µL 
Preglednica 5 Trajanje zvečanja števila trombocitov na ≥ 50.000/µl
In the human mass balance study using [14C]-lusutrombopag, unchanged lusutrombopag (97% of radioactivity in plasma) was the major circulating component, and the metabolites, such as deshexyl, β-oxidated carboxylic acid, taurine conjugate of β-oxidated carboxylic acid, and acyl glucuronide, were detected with less than 2.6% of radioactivity in plasma. 
V študiji masnega ravnovesja pri človeku, v kateri so uporabili [14C]-lusutrombopag, je bil nespremenjeni lusutrombopag (97 % radioaktivnosti v plazmi) poglavitna sestavina v krvi, presnovki, na primer desheksil, β-oksidirano karboksilno kislino, konjugat tavrina z β-oksidirano karboksilno kislino in acil-glukuronid, pa so predstavljali manj kot 2,6 % radioaktivnosti v plazmi.
- The other ingredients are: - Tablet core: mannitol, microcrystalline cellulose, magnesium oxide, sodium lauryl sulfate, hydroxypropylcellulose, carmellose calcium and magnesium stearate - Film coating: hypromellose, titanium dioxide, triethyl citrate, talc and red-ferric oxide (E172) 
- Druge sestavine zdravila so: - sredica tablete: manitol, mikrokristalna celuloza, magnezijev oksid, natrijev lavrilsulfat, hidroksipropilceluloza, kalcijev karmelozat in magnezijev stearat; - filmska obloga: hipromeloza, titanov dioksid, trietilcitrat, smukec in rdeči železov oksid (E172).
The most common adverse reactions were headache (4.7%, 8/171 patients in the lusutrombopag group; 3.5%, 6/170 patients in the placebo group), nausea (2.3%, 4/171 patients in the lusutrombopag group; 4.1%, 7/170 patients in the placebo group), portal vein thrombosis (1.2%, 2/171 patients in the lusutrombopag group; 1.2%, 2/170 patients in the placebo group) and rash (1.2%, 2/171 patients in the lusutrombopag group; 0%, 0/170 patients in the placebo group). 
Najpogostejši neželeni učinki so bili glavobol (4,7 %, 8/171 bolnikov v skupini z lusutrombopagom; 3,5 %, 6/170 bolnikov v skupini s placebom), navzea (2,3 %, 4/171 bolnikov v skupini z lusutrombopagom; 4,1 %, 7/170 bolnikov v skupini s placebom), tromboza portalne vene (1,2 %, 2/171 bolnikov v skupini z lusutrombopagom; 1,2 %, 2/170 bolnikov v skupini s placebom) in izpuščaj (1,2 %, 2/171 bolnikov v skupini z lusutrombopagom; 0 %, 0/170 bolnikov v skupini s placebom).
The pharmacokinetic parameters in patients with chronic liver disease are shown in Table 6. 
Farmakokinetične parametre pri bolnikih s kronično boleznijo jeter kaže preglednica 6.
There is no specific antidote for lusutrombopag overdose. 
Za preveliko odmerjanje lusutrombopaga ni specifičnega antidota.
- Use reliable methods of contraception while you are taking Mulpleo. 
- Tačas ko jemljete zdravilo Mulpleo, uporabljajte zanesljive kontracepcijske metode.
The differences in pharmacokinetics of a single 0.75 mg dose of lusutrombopag were relatively small in both subjects with mild hepatic impairment and subjects with moderate hepatic impairment, compared with the healthy matched control group. 
Razlike v farmakokinetiki enkratnega odmerka 0,75 mg lusutrombopaga so bile razmeroma majhne tako pri bolnikih z blago okvaro jeter kot pri bolnikih z zmerno okvaro jeter v primerjavi s kontrolno skupino zdravih oseb s primerljivimi demografskimi podatki.
Common side effects (may affect up to 1 in 10 people) 
(lahko se pojavijo pri največ 1 od 10 bolnikov)